etherna
Galileilaan 19
2845 Niel
BE
etherna
Foundation date
21/01/2013
Sector
#Biotechnology - TherapeuticsSubsector
eTheRNA BVBA is a spin-off company from VUB. The company was created in 2013 by Prof. Kris Thielemans out of the Laboratory of Molecular and Cellular Therapy (LMCT). eTheRNA is currently focused on the manufacturing of mRNA based drugs/vaccines to support clinical development and diagnostic applications. The aim is to grow into a Flanders based biopharma company that will develop a leadership position in not only mRNA manufacturing but also developing mRNA based drugs that enhance the immunological response against certain targeted diseases/indications.
Upcoming events
All events-
1012 '24
Next-Generation Synthetic Biology
Event by: VIB -
0312 '24
BioFIT 2024
Event by: Eurasanté -
0204 '25
The Franco-Belgian Agrifood Summit
Event by: CCI France - Belgique
News by etherna
More news-
mRNA leading expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers investing in EUR 39M Series B2 financing of mRNA technology platform company eTheRNA
Tuesday August 23rd 2022
Read more
-
eTheRNA Manufacturing announces new LNP formulation development and production service
Tuesday March 29th 2022
Read more
-
eTheRNA announces research agreement with Merck to access mRNA technologies
Thursday February 3rd 2022
Read more
Jobs
More jobs-
-
-
20/11/24
Antwerp
Postdoc position in the Laboratory for Gut-Immune-Brain Axis Research
Permanent
VIB
More info?
Ellen Telleir
Communication Coordinator